From: What is the future of targeted therapy in rheumatology: biologics or small molecules?
Ligand | Jak-kinase |
---|---|
IL-6, IL-11, CNTF, CT-1, LIF, OSM, IL-27 (EBI3 + p28), IL-31, IL-35 (p35 + EBI3) | Jak1, Jak2, Tyk2 |
G-CSF, IL-12 (p40 + p35), angiotensin | Jak2, Tyk2 |
Leptin, GM-CSF, IL-5, IL-3, IL-23 (p40 + p19), serotonin, α-thrombin | Jak2 |
Chemokines | Jak2, Jak3 |
IL-2 | Jak1, Jak2, Jak3 |
IL-4, IL-9, IL-7, IL-15, IL-21 | Jak1, Jak3 |
IL-13 | Jak1, Jak2, Tyk2 |
IL-19, IL-20 | Jak1, ? |
IL-22, IL-26, IL-28A, IL-28B, IL-29, interferon (IFNα/β), IL-10 | Jak1, Tyk2 |
IL-24 | Jak1, ? |
GH, Epo | Jak2 |
Thrombopoetin | Jak2, Tyk2 |
IFN-γ, PDGF | Jak1, Jak2 |
TLSP | Jak1, possibly Jak2 |
EGF | Jak1 |